ROGER TELL

MD, PhD/Chief Medical Officer

Dr. Roger Tell is and responsible for medical and scientific issues at Isofol. Dr. Tell joined Isofol in 2019 as Senior Vice President of Clinical Development, Chief Scientific Officer and Chief Medical Officer. He has also been acting CEO for a period. He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Paris, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. He is board member in Vivesto which is listed on Nasdaq Stockholm. Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.

Roger has a consulting assignment as CMO since January 2024.

Position: Chief Medical Officer

Holdings: 0 shares*

Contact:
E-mail: roger.tell@isofolmedical.com

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of June 30, 2024.